Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Mar 12, 2010


Taylor Technology this week announced it is offering the Fast PK service, which can perform a complete pharmacokinetic study in five days or less.

Typically, pharmacokinetic studies take weeks to complete.

Taylor is a subsidiary of PharmaNet Development Group and specializes in mass spectrometry and immunochemistry for drug discovery and development analysis.

Fast PK is part of PharmaNet's strategic alliance with Aniclin Preclinical Services, and allows Taylor to leverage Aniclin's complementary services, "as well as cutting edge technology to enhance bioanalytical program support and in vivo services," Taylor said in a statement.

Fast PK includes formulation, dosing, PK sampling, transfer of samples to the lab, and bioanalysis of six time points "inclusive of quality control samples and front and back standard curves," Taylor said. "The accelerated timeline involves the new chemical entities arriving at Aniclin where dosing is performed." Collected plasma samples are sent within two hours to Taylor, where they are then immediately processed for LC-MS/MS analysis.

Taylor uses Thermo Fisher Scientific's Exactive LC-MS system for semi-quantitative metabolite analysis data during the Fast PK assay.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.